Amgen's Weight-Loss Drug Shows Promise With Less Frequent Dosing

Amgen reported early Phase 2 data suggesting patients kept weight off with less frequent dosing, a potential differentiator from Eli Lilly and Novo Nordisk.

Barrons • Jan 15, 2026

Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses

At a J.P. Morgan Healthcare Conference on Monday, Amgen Inc. (NASDAQ: AMGN) CEO Robert Bradway shared findings from part 2 of the Phase 2 Study of MariTide, its investigational obesity treatment.

Benzinga • Jan 14, 2026

Amgen (AMGN) Advances While Market Declines: Some Information for Investors

In the latest trading session, Amgen (AMGN) closed at $328.97, marking a +1.44% move from the previous day.

Zacks Investment Research • Jan 14, 2026

Amgen CEO: There are a bunch of ways to win for patients when it comes to weight loss

Amgen CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk its rare disease business, its weight-loss drug offering, what is in Amgen's pipeline, and more.

CNBC Television • Jan 14, 2026

Amgen CEO Bob Bradway goes one-on-one with Jim Cramer

Amgen CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk its rare disease business, its weight-loss drug offering, what is in Amgen's pipeline, and more.

CNBC Television • Jan 14, 2026

Amgen CEO says weight loss drug can address 'patient persistence issue'

Amgen CEO Bob Bradway told CNBC's Jim Cramer he thinks his company's obesity drug can help patients maintain weight loss, which he indicated is a challenge. "We think we can address one of the reasons that the field is struggling a little bit, which is the patient persistence issue," Bradway said.

CNBC • Jan 13, 2026

Ro partners with Amgen to study barriers to obesity care, GLP-1 access

U.S. telehealth firm Ro said on Tuesday it has entered a research collaboration with drugmaker Amgen to examine challenges patients and providers face in accessing obesity treatments, including GLP-1 therapies.

Reuters • Jan 13, 2026

Amgen to announce data on obesity drug MariTide at healthcare conference

Amgen's research chief said the company is very confident about its experimental obesity drug MariTide, as it prepares on Monday to unveil results from a mid-stage trial extension designed to show if the medication helps people maintain weight loss.

Reuters • Jan 12, 2026

Amgen says MariTide helped trial patients maintain weight loss

An extension study of Amgen's experimental obesity drug MariTide found that it helped people maintain weight loss while a second mid-stage trial in diabetes patients showed that it lowered their blood sugar and weight, the company said on Monday.

Reuters • Jan 13, 2026

Amgen Inc. (AMGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Amgen Inc. (AMGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 13, 2026